B型肝炎ウイルス（HPV）治療市場：ヨーロッパ主要国の治療薬市場...市場調査レポートについてご紹介

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Overview
3.2 Etiology and Pathophysiology
3.2.1 Etiology
3.2.2 Pathophysiology
3.3 Symptoms
3.4 Prognosis
3.4.1 Phases of Chronic HBV Infection
3.4.2 Complications of Chronic Hepatitis B
3.5 Quality of Life
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Diagnosis
4.1.2 Treatment Guidelines and Leading Prescribed Drugs
4.1.3 Clinical Practice
4.2 5EU
4.2.1 Screening and Diagnosis
4.2.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Product Profiles – Major Brands
5.2.1 Baraclude (entecavir)
5.2.2 Viread (tenofovir disoproxil fumarate)
5.2.3 Pegasys (peginterferon alfa-2a)
5.2.4 Hepsera (adefovir dipivoxil)
5.2.5 Tyzeka (telbivudine)
5.3 Other Therapeutics
5.3.1 Conventional and Pegylated Interferon alfa
5.3.2 Nucleos(t)ide Analogs
6 Unmet Need and Opportunity
6.1 Overview
6.2 Improvements in Long-Term Clinical Outcomes
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Enhanced Public Awareness and Screening Initiatives to Boost Diagnosis Rates
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Increased Access to Treatment
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Drugs That Effectively Target and Suppress HBV cccDNA
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
6.6 Safe and Efficacious Therapies for Difficult-to-Treat Patients
6.6.1 Unmet Need
6.6.2 Gap Analysis
6.6.3 Opportunity
6.7 Overcome Unique Barriers Posed by China’s Healthcare System
6.7.1 Unmet Need
6.7.2 Gap Analysis
6.7.3 Opportunity
7 Pipeline Assessment
7.1 Overview
7.2 Clinical Trial Mapping
7.2.1 Clinical Trials by Phase and Status, Therapy Class, and Location
7.3 Promising Drugs in Clinical Development
7.3.1 Tenofovir Alafenamide Fumarate
7.3.2 ARC-520
7.3.3 GS-9620
7.3.4 GS-4774
7.4 Other Drugs in Development
7.4.1 ABX-203
7.4.2 REP 2139-Ca
7.4.3 Besifovir
7.4.4 Hepabulin
7.4.5 Myrcludex-B
7.4.6 Agents in Early Stages of Development
8 Market Outlook
8.1 5EU
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Total Prevalent Cases of Chronic Hepatitis B
9.4.2 Diagnosed Chronic Hepatitis B Patients
9.4.3 Percent Drug-Treated Chronic Hepatitis B Patients
9.4.4 Drugs Included in Each Therapeutic Class
9.4.5 Launch and Patent Expiry Dates
9.4.6 General Pricing Assumptions
9.4.7 Individual Drug Assumptions
9.4.8 Generic Erosion
9.4.9 Pricing of Pipeline Agents
9.5 Primary Research – KOLs Interviewed for this Report
9.6 Primary Research – Prescriber Survey
9.7 About the Authors
9.7.1 Analyst
9.7.2 Therapy Area Director
9.7.3 Epidemiologists
9.7.4 Global Director of Therapy Analysis and Epidemiology
9.7.5 Global Head of Healthcare
9.8 About GlobalData
9.9 Disclaimer